Table 3.
Coronary artery aneurism or dilatation associated factors.
| Frequency in the aneurism/dilatation group N = 27 (%) | Unadjusted OR (95% CI)a | p-value | OR adjusted for centerb | p-value | |
|---|---|---|---|---|---|
| Sex (male) | 19/27 (70.4%) | 2.20 (0.99–4.9) | 0.05 | 1.71 (0.63–4.58) | 0.29 |
| Age ≥10 years | 5/27 (18.5%) | 0.31 (0.05–2.04) | 0.22 | 0.55 (0.17–1.80) | 0.32 |
| ≥10 days with symptoms before admission | 10/25 (40%) | 4.16 (2.61–6.23) | <0.001 | 1.62 (1.19–2.04) | <0.001 |
| Positive SARS-COV-2 RT-PCR or rapid antigen test | 12/20 (60%) | 0.70 (0.13–3.73) | 0.67 | 1.11 (0.31–3.96) | 0.87 |
| Positive SARS-COV-2 serology | 16/20 (80%) | 2.58 (0.77–8.64) | 0.125 | 1.45 (0.36–5.89) | 0.60 |
| Obesity (BMI > 95th percentile) | 16/20 (80%) | 1.04 (0.53–2.04) | 0.92 | 1.40 (0.37–5.37) | 0.63 |
| Rash | 9/27 (33%) | 0.49 (0.10–2.29) | 0.36 | 0.69 (0.25–1.91) | 0.48 |
| Conjunctivitis | 17/27 (63.0%) | 1.5 (0.33–6.92) | 0.60 | 1.82 (0.57–5.77) | 0.31 |
| Gastrointestinal | 16/27 (59.3%) | 0.39 (0.10–1.49) | 0.17 | 0.70 (0.22–2.15) | 0.54 |
| Severe respiratory dysfunction | 11/27 (40.74%) | 1.53 (0.63–3.71) | 0.35 | 1.56 (0.59–4.18) | 0.37 |
| Arthralgias/Myalgias | 2/27 (4.41%) | 0.21 (0.05–0.94) | 0.04 | 0.13 (0.02–0.67) | 0.015 |
| Mucocutaneous involvement | 13/27 (48.15%) | 0.35 (0.17–0.70) | 0.003 | 0.74 (0.25–2.17) | 0.59 |
| Neutrophilia (>7,500 cells/mcl) | 19/27 (70.37%) | 2.13 (0.82–5.58) | 0.12 | 1.87 (0.67–5.22) | 0.23 |
| Lymphopeniac | 15/27 (55.56%) | 0.52 (0.20–1.31) | 0.17 | 0.40 (0.15–1.10) | 0.08 |
| Platelets count <150,000 cell/mcl | 7/27 (25.93%) | 0.48 (0.17–1.40) | 0.18 | 0.48 (0.16–1.37) | 0.17 |
| Fibrinogen >400 mg/dl | 11/21 (52.38%) | 0.68 (0.26–1.75) | 0.42 | 0.86 (0.31–2.37) | 0.77 |
| Ferritin >300 mg/dl | 18/20 (90%) | 4.39 (0.81–23.89) | 0.09 | 4.50 (0.90–22.5) | 0.07 |
| D-Dimer >560 ng/ml (0.56 ng/L) | 24/26 (92.3%) | 1.64 (0.41–6.47) | 0.48 | 0.97 (0.17–5.66) | 0.98 |
| C-reactive protein >5 mg/L | 26/27 (96.3%) | 2.41 (0.47–12.4) | 0.29 | 2.68 (0.28–25.31) | 0.39 |
| Procalcitonin >0.15 ng/ml | 15/23 (65.2%) | 0.45 (0.27–0.76) | 0.003 | 0.84 (0.23–3.00) | 0.75 |
| Albumin <3 g/dl | 20/27 (74.07%) | 1.83 (0.72–4.62) | 0.20 | 1.62 (0.57–4.63) | 0.90 |
| INR > 1.2 | 14/27 (51.85%) | 1.37 (0.54–3.54) | 0.50 | 2.45 (0.86–7.00) | 0.093 |
| LVEFd < 55% | 8/25 (32%) | 1.25 (0.30–5.1) | 0.76 | 1.49 (0.50–4.47) | 0.45 |
| Alanine Aminotransferase >90 U/L | 4/25 (16%) | 0.53 (0.19–1.43) | 0.21 | 0.97 (0.26–3.70) | 0.97 |
| Intravenous immune globulin | 27/27 (100%) | – | – | – | – |
| Systemic steroids | 21/27 (77.78%) | 0.9 (0.16–4.93) | 0.90 | 0.96 (0.27–3.3) | 0.95 |
| Group 1 (TSS-like) | 7/27 (25.9%) | 1 (reference) | – | 1 (reference) | – |
| Group 2 (Kawasaki-like) | 9/27 (33.3%) | 1.14 (0.29–4.45) | 0.85 | 0.66 (0.17–2.58) | 0.55 |
| Group 3 (Unespecific presentation) | 11/27 (40.7%) | 1.25 (0.25–6.15) | 0.78 | 0.59 (0.15–2.31) | 0.45 |
a
Clustered robust standard error adjustment.
b
OR adjusted for center with multilevel mixed-effects logistic regression.
c
Lymphopenia: <2 years: <4,000, 2–3 years: <3,000, >4 years: <1,500 cells/mcl.
d
LVEF, Left ventricular ejection fraction.